Melanoma Cancer CPG Mini-Module – Management of melanoma brain metastases

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.

In this case study presentation, Elizabeth Buchbinder, MD, of Dana-Farber Cancer Institute and April Salama, MD, of the Duke Cancer Institute address the guidelines for the management of melanoma brain metastases. Dr. Buchbinder also outlines current options for front-line treatment of advanced disease and patient-specific considerations associated with each option. This mini-module ends with a discussion between Drs. Buchbinder and Salama about the potential benefits and unanswered questions surrounding adoptive cellular therapy for melanoma.

Run time: Approximately 10 minutes

Target Audience
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants, and radiologists. 

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described
in this educational activity. 

The Mini Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.